Cyclooxygenase inhibitors reduce biofilm formation and yeast-hypha conversion of fluconazole resistant Candida albicans

Journal of Microbiology

Volumn 51, Issue 5, 2013, Pages 598-604

  Abdelmegeed, E ^a   Shaaban, Mona Ibrahim ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

biofilm; C. albicans; cyclooxygenase inhibitors; fluconazole resistant; morphology; prostaglandin

Indexed keywords

CANDIDA; CANDIDA ALBICANS; FUNGI;

ANTIFUNGAL AGENT; FLUCONAZOLE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; BIOFILM; CANDIDA ALBICANS; CELL ADHESION; DRUG EFFECT; FUNGUS HYPHAE; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PHYSIOLOGY;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; CELL ADHESION; CYCLOOXYGENASE INHIBITORS; FLUCONAZOLE; HYPHAE;

EID: 84887991016     PISSN: 12258873     EISSN: 19763794     Source Type: Journal    
DOI: 10.1007/s12275-013-3052-6     Document Type: Article

References (46)

1. Abdi-Ali, A., Mohammad-Mehr, M., and Agha, A. 2005. Bactericidal activity of various antibiotics against biofilm producing Pseudomonas aeruginosa. Int. J. Antimicrob. Agents27, 196-200.
2. Alem, M. A. and Douglas, L. J. 2004. Effects of aspirin and other nonsteroidal anti-inflammatory drugs on biofilms and planktonic cells of Candida albicans. Antimicrob. Agents Chemother. 48, 41-47.
3. Alem, M. A. and Douglas, L. J. 2005. Prostaglandin production during growth of Candida albicans biofilms. J. Med. Microbiol. 54, 1001-1005.
4. Alves, S. H., Milan, E. P., Sant'ana, P. L., Olivera, L. O., Santurio, J. M., and Colombo, A. L. 2002. Hypertonic sabouraud broth as a simple and powerful test for Candida dubliniensis screening. Diagn. Microbiol. Infect. Dis. 43, 85-86.
5. Baillie, G. S. and Douglas, L. J. 1999. Role of dimorphism in the development of Candida albicans biofilms. J. Med. Microbiol. 48, 671-679.
6. Bink, A., Kucharíková, S., Neirinck, B., Vleugels, J., van Dijck, P., Cammue, B. P., and Thevissen, K. 2012. The nonsteroidal antiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms. J. Infect. Dis. 1, 790-797.
7. Bink, A., Pellens, K., Cammue, B. P., and Thevissen, K. 2011. Antiiofilm strategies: How to eradicate Candida biofilms?. Open Mycol. J. 5, 29-38.
8. Blankenship, J. R. and Mitchell, A. P. 2006. How to build a biofilm: a fungal perspective. Curr. Opin. Microbiol. 9, 588-594.
9. Calderone, R. A. and Fonzi, W. A. 2001. Virulence factors of Candida albicans. Trends Microbiol. 9, 327-335.
10. Cannon, R. D. and Chaffin, W. L. 1999. Oral colonization by Candida albicans. Crit. Rev. Oral Biol. Med. 10, 359-383.
11. DeQuadros, A. U., Bini, D., Pereira, P. A., Moroni, E. G., and Monteiro, M. C. 2011. Antifungal activity of some cyclooxygenase inhibitors on Candida albicans: PGE2-dependent mechanism. Folia Microbiol. (Praha) 56, 349-352.
12. Deva, R., Ciccoli, R., Kock, L., and Nigam, S. 2001. Involvement of aspirin sensitive oxylipins in vulvovaginal candidiasis. FEMS Microbiol. Lett. 198, 37-43.
13. Deva, R., Ciccoli, T., Schewe, J. L., Kock, F., and Nigam, S. 2000. Arachidonic acid stimulates cell growth and forms a novel oxygenated metabolite in Candida albicans. Biochim. Biophys. Acta. 1486, 299-311.
14. Douglas, L. J. 2003. Candida biofilms and their role in infection. Trends Microbiol. 11, 30-36.
15. Eliopoulos, G. M. and Moellering, R. C. 1996. Antimicrobial combinations, pp. 330-396. In Lorian, V. (ed). Antibiotics in laboratory medicine. Williams and Wilkins, Baltimore, USA.
16. th ed., pp. 387-540. J. P. Lipincott Company, Philadelphia, USA.
17. Erb-Downward, J. R. and Noverr, M. C. 2007. Characterization of prostaglandin E2 production by Candida albicans. Infect. Immun. 75, 3498-3505.
18. Ghalehnoo, Z. R., Rashki, A., Najimi, M., and Dominguez, A. 2010. The role of diclofenac sodium in the dimorphic transition in Candida albicans. Microb. Pathog. 48, 110-115.
19. Ghormade, V. and Deshpande, M. V. 2000. Fungal spore germination into yeast or mycelium: possible implications of dimorphism in evolution and human pathogenesis. Naturwissen-Schaften. 87, 236-240.
20. Harriott, M. M. 2009. Effects of prostaglandin E2 on Candida albicans biofilms. ETD Collection for Wayne State University. Paper AAI 3372009.
21. Hawser, S. P. and Douglas, L. J. 1995. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother. 39, 2128-2131.
22. Hube, B. 2006. Infection-associated genes of Candida albicans. Future Microbiol. 1, 209-218.
23. Kojic, E. M. and Darouiche, R. O. 2004. Candida infections of medical devices. Clin. Microbiol. Rev. 17, 255-267.
24. Lewis, R. E., Diekema, D. J., Messer, S. A., Pfaller, M. A., and Klepser, M. E. 2002. Comparison of E test, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J. Antimicrob. Chemother. 49, 345-351.
25. Marinho, S. A., Teixeira, A. B., Santos, O. S., Cazanoval, R. F., Ferreira, C. A. S., Cherubini, K., and de'Oliveira, S. D. 2010. Identification of Candida spp. By phenotypic tests and PCR. Braz. J. Microbiol. 41, 286-294.
26. Mukherjee, P. K., Chandra, J., Kuhn, D. M., and Ghannoum, M. A. 2003. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect. Immun. 71, 4333-4340.
27. Nett, J. E., Guite, K. M., Ringeisen, A., Holoyda, K. A., and Andes, D. R. 2008. Reduced biocide susceptibility in Candida albicans biofilms. Antimicrob. Agents Chemother. 52, 3411-3413.
28. Noverr, M. C., Erb-Downward, J. R., and Huffnagle, G. B. 2003. Production of eicosanoids and other oxylipins by pathogenic eukaryotic microbes. Clin. Microbiol. Rev. 16, 517-533.
29. Noverr, M. C., Phare, S. M., Toews, G. B., Coffey, M. J., and Huffnagle, G. B. 2001. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect. Immun. 69, 2957-2963.
30. Noverr, M. C., Toews, G. B., and Huffnagle, G. B. 2002. Production of prostaglandins and leukotrienes by pathogenic fungi. Infect. Immun. 70, 400-402.
31. Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K. Jr., Calandra, T. F., Edwards, J. E. Jr., Filler, S. G., Fisher, J. F., Kullberg, B. J., Ostrosky-Zeichner, L., andet al. 2009. Clinical practice guidelines for the management of candidiasis. Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 503-535.
32. Perlroth, J., Choi, B., and Spellberg, B. 2007. Nosocomial fungal infections: epidemiology, diagnosis and treatment. Med. Mycol. 45, 321-346.
33. Pfaller, M. A., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rex, J. H., Rinaldi, M. G., Sheehan, D. J., Walsh, T. J., and et al. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard NCCLS document M27-A2. National Committee for Clinical Laboratory Standards. 22(15), Wayne, PA, USA.
34. Pfaller, M. A. and Diekma, D. J. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20, 133-163.
35. Pfaller, M., Gordee, R., Gerarden, T., Yu, M., and Wenzel, R. 1989. Fugicidal activity of cilofungin (LY12019) alone and in combination with anticapsin or other antifungal agents. Eur. J. Clin. Microbiol. Infect. Dis. 8, 564-567.
36. Pina-Vaz, C., Sansonetty, F., Rodrigues, A. G., Martinez-De-Oliveira, J., Fonseca, A. F., and Mardh, P. A. 2000. Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species. J. Med. Microbiol. 49, 831-840.
37. Plerce, C. G., Thomas, D. P., and Lopez-Ribol, J. L. 2009. Effect of tunicamycin on Candida albicans biofilm formation and maintenance. J. Antimicrob. Chemother. 63, 473-479.
38. Ramage, G., Saville, S. P., Thomas, D. P., and Lopez-Ribot, J. L. 2005. Candida biofilms. Eukaryot Cell. 4, 633-638.
39. Ramage, G., Vondewalle, K., Wickes, B. L., and Lopez-Ribot, J. L. 2001. Biofilm formation by Candida dulininensis. J. Clin. Microbiol. 39, 3234-3240.
40. Scott, E. M., Tariq, V. N., and McCrory, R. M. 1995. Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Antimicrob. Agents Chemother. 39, 2610-2614.
41. Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W., and Azeredo, J. 2012. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol. Rev. 36, 288-305.
42. Slifkin, M. 2000. Tween 80 test responses of various Candida species. J. Clin. Microbiol. 38, 4626-4628.
43. Stepanovic, S., Vukovic, D., Dalc, I., Savic, B., and Svabio-vlalovic, M. A. 2000. Modified microtitre plate test for quantification of staphylococcal biofilm formation. J. Microbiol. Methods40, 175-179.
44. Whiteway, M. and Bachewich, C. 2007. Morphogenesis in Candida albicans. Ann. Rev. Microbiol. 61, 529-553.
45. Whiteway, M. and Oberholzer, U. 2004. Candida morphogenesis and host-pathogen interactions. Curr. Opin. Microbiol. 7, 350-357.
46. Zhou, Y., Wang, G., Li, Y., Liu, Y., Song, Y., Zheng, W., Zhang, N., Hu, X., Yan, S., and Jia, J. 2012. In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of C. albicans and C. parapsilosis. Antimicrob. Agents Chemother. 56, 2350-2360.